ondansetron has been researched along with Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted in 1 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Profound fatigue is a clinically significant complication of chronic liver disease." | 1.33 | Personal view: a potential novel treatment for fatigue complicating chronic liver disease--how should its efficacy be evaluated? ( Jones, EA, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jones, EA | 1 |
1 other study available for ondansetron and Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted
| Article | Year |
|---|---|
Personal view: a potential novel treatment for fatigue complicating chronic liver disease--how should its efficacy be evaluated?
Topics: Fatigue; Hepatitis C; Humans; Liver Cirrhosis, Biliary; Liver Diseases; Ondansetron; Randomized Cont | 2006 |